Sagimet Biosciences issues pre-funded warrants in $10.00-per-share offering
Bitget2026/10/01 10:03- Sagimet Biosciences entered an underwriting agreement for an underwritten offering that includes pre-funded warrants for up to 2,750,010 shares.
- Pre-funded warrants priced at USD 9.9999 per share issuable; exercise price USD 0.0001; immediately exercisable from issuance.
- Warrant exercises limited to 4.99% beneficial ownership, or 9.99% at the holder’s election; adjustable up to 19.99% with 61 days’ notice.
- Offering also includes 8,750,010 common shares at USD 10.00; expected to close Oct. 1, 2026; net proceeds seen at USD 107.5 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Plasma is now live on the Pump.fun application

The US dollar marks its fourth consecutive week of gains
The US dollar is expected to rise for the fourth consecutive week, having gained over 3% this year. Anthropic surged by 17% on its first day of trading on Nasdaq, with overseas subscriptions reaching approximately 10 to 15 billion dollars, driving increased demand for foreign exchange. Additionally, the 10-year US Treasury yield remains above 5%, and the Federal Reserve's meeting minutes suggest another potential rate hike. Institutions predict the dollar's strength will continue until 2027.

DCTY dropped over 72% in 24 hours, with its current market capitalization at $3.8 million.

Citigroup's (C.US) European subsidiary made a trading accounting error, resulting in a $35 billion understatement of risk-weighted assets
It is reported that a Citi subsidiary underestimated risk assets by 35 billions USD.
